CoChat
Sign Up
Cited by 185

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial

Herring, W. Joseph, Ceesay, Paulette, Snyder, Ellen, Bliwise, Donald, Budd, Kerry, Hutzelmann, Jill, Stevens, Joanne, Lines, Christopher, Michelson, David·2020·Alzheimer's & Dementia
DOI 10.1002/alz.12035PMC PMC7984350
Open this paper in CoChat — free account

Abstract

Introduction: We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild‐to‐moderate probable Alzheimer's disease (AD) dementia. Methods: Randomized, double‐blind, 4‐week trial of suvorexant 10 mg (could be increased to 20 mg based on clinical response) or placebo in patients who met clinical diagnostic criteria for both probable AD dementia and insomnia. Sleep was assessed by overnight polysomnography in a sleep laboratory. The primary endpoint was change‐from‐baseline in polysomnography‐derived total sleep time (TST) at week 4. Results: Of 285 participants randomized (suvorexant, N = 142; placebo, N = 143), 277 (97%) completed the trial (suvorexant, N = 136; placebo, N = 141). At week 4, the model‐based least squares mean improvement‐from‐baseline in TST was 73 minutes for suvorexant and 45 minutes for placebo; (difference = 28 minutes [95% confidence interval 11‐45], p < 0.01). Somnolence was reported in 4.2% of suvorexant‐treated patients and 1.4% of placebo‐treated patients. Discussion: Suvorexant improved TST in patients with probable AD dementia and insomnia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12035

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most therapies approved for Alzheimer's disease are indicated to only treat symptoms: acetylcholinesterase inhibitors, a glutamatergic modulator (memantine), and an orexin receptor antagonist (suvorexant) for Alzheimer-related insomnia.

    “Most therapies approved for Alzheimer’s disease are indicated to only treat the symptoms of Alzheimer’s disease: acetylcholinesterase inhibitors, a glutamatergic modulator (memantine), and an orexin receptor antagonist (suvorexant) for Alzheimer-related insomnia [21,22].”

    From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [22]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. 10.1016/j.tins.2016.05.002 · DOI
  2. 10.1038/nrn.2017.55 · DOI · Paper page
  3. 10.1016/j.nbscr.2016.08.002 · DOI
  4. 10.1073/pnas.1721694115 · DOI · Paper page
  5. 10.1126/scitranslmed.aau6550 · DOI
  6. 10.1272/jnms.70.334 · DOI
  7. 10.1097/JGP.0b013e318187de18 · DOI
  8. 10.1002/gps.760 · DOI
  9. 10.1093/sleep/26.7.893 · DOI · Paper page
  10. 10.1177/0891988704264535 · DOI
  11. 10.1016/j.pnpbp.2006.09.001 · DOI
  12. Yin Y, 2015, Low‐dose atypical antipsychotic risperidone improves the 5‐year outcome in Alzheimer's disease Patients with sleep disturbances, Pharmacology, 96, 155, 10.1159/000435889 · DOI
  13. 10.1111/psyg.12191 · DOI · Paper page
  14. 10.1016/j.archger.2007.07.010 · DOI
  15. 10.1016/j.jagp.2013.12.174 · DOI · Paper page
  16. 10.1002/gps.2609 · DOI
  17. 10.1136/jnnp.2006.104034 · DOI
  18. 10.1017/S1041610298005353 · DOI
  19. 10.1021/jm100541c · DOI
  20. 10.3109/01677063.2011.566953 · DOI
  21. 10.1016/j.biopsych.2014.10.003 · DOI
  22. 10.5664/jcsm.6116 · DOI
  23. 10.1016/j.jagp.2017.03.004 · DOI
  24. 10.1212/WNL.0b013e31827688ee · DOI
  25. 10.1016/S1474-4422(14)70053-5 · DOI
  26. 10.1016/j.neurobiolaging.2011.03.014 · DOI
  27. 10.1007/s00415-017-8613-x · DOI
  28. 10.1007/7854_2016_50 · DOI
  29. 10.1016/j.neurobiolaging.2017.01.011 · DOI
  30. 10.1016/j.neurobiolaging.2016.01.007 · DOI
  31. 10.1176/appi.books.9780890425596 · DOI · Paper page
  32. 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  33. Busner J, 2007, The clinical global impressions scale: applying a research tool in clinical practice, Psychiatry (Edgmont), 4, 28
  34. 10.5664/jcsm.26814 · DOI · Paper page
  35. Berry RB BR, 2015, The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2
  36. 10.1046/j.0962-1105.2003.00374.x · DOI
  37. 10.5664/jcsm.6470 · DOI · Paper page
  38. 10.1016/j.sleep.2015.10.007 · DOI
  39. 10.1016/j.jalz.2015.06.1893 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Herring, W. J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J., Lines, C., & Michelson, D.
Affiliations
  • Merck &amp; Co., Inc. Kenilworth New Jersey
  • Sleep Center Emory University School of Medicine Atlanta Georgia
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2020-01-15
Volume
16
Issue
3
Pages
541-551
ISSN
  • 1552-5260
  • 1552-5279
DOI
10.1002/alz.12035
PMC
PMC7984350
Cited by
185
References
7
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Funders
Merck Sharp and Dohme

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review